medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (1)


Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis

Landeira G, Morise S, Fassio E, Ramonet M, Álvarez E, Caglio P, Longo C, Domínguez N

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 100-106
Archivo PDF: 99.73 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McFarlane IG. Definition and classification of autoimmune hepatitis. Semin Liver Dis 2002; 22: 317-24.

  2. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002; 22: 365-77.

  3. Johnson PJ, McFarlane IG, convenors, on behalf of the panel. Meeting Report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.

  4. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cançado EL, Chapman RW, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.

  5. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, et al. Simplified criteria for the diagnosis of autoinmune hepatitis. Hepatology 2008; 48: 169-76.

  6. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.

  7. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.

  8. Soloway RD, Summerskill WHJ, Bagentoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatment and early prognosis. Gastroenterology 1972; 63: 820-33.

  9. Wright EC, Seef LB, Berk PD, Jones EA, Plotz PH. Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology 1977; 73: 1422-30.

  10. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21: 78-83.

  11. Heneghan MA, McFarlane IG. Current and novel immunosupresive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13.

  12. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.

  13. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.

  14. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.

  15. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 1987; 7: 1333-9.

  16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  17. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.

  18. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.

  19. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 507-15.

  20. Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, Sakai N, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-7.

  21. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission, and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6.

  22. Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergquist A, Prytz H, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45: 457-67.




2020     |     www.medigraphic.com